Simple Summary KRAS G12C mutations are important oncogenic mutations in lung cancer
that can now be targeted by allosteric small molecule inhibitors. We assessed the imaging …

Purpose: KRAS mutations are identified in approximately 30% of patients with non–small
cell lung cancer (NSCLC). Novel direct inhibitors of KRAS G12C have shown activity in early …

The development of covalent inhibitors against KRAS G12C represents a major milestone in
treatment of RAS-driven cancers, especially in non-small cell lung cancer (NSCLC), where …

Background KRAS mutations are found in 20–30% of non-small cell lung cancers (NSCLC)
and were traditionally considered undruggable. KRAS G12C mutation confers sensitivity to …

Background Real-world data on demographics related to KRAS mutation subtypes are
crucial as targeted drugs against the p. G12C variant have been approved. Method We …

Introduction KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are
currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C …

Lung malignant tumors are a type of cancer with high incidence and mortality rates
worldwide. Non-small cell lung cancer (NSCLC) accounts for over 80% of all lung malignant …

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to
clinical development—a narrative review - PMC Back to Top Skip to main content NIH NLM …

KRas mutations are frequently seen in solid tumors such as lung (~ 25%), colorectal (~ 40%)
and pancreatic (~ 90%) cancers. The G12C mutation accounts for~ 50% of all KRas …

Background In light of the ongoing clinical development of KRAS G12D-specific inhibitors,
we sought to investigate the clinicopathologic, co-occurring genomic features and outcomes …